T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
TOP PICK

Pfizer Inc(PFE)

Sep 18, 2006
Good value for a bounce. Expects another 15/20% upside. Treating it as a Trade, not for the long term.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$28.16

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2006
Likes it and still buying for new clients. Have a pipeline of new drugs and using their cash to develop new drugs. Have sold their consumer products division. Have increased their dividends and doing buybacks.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.98

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 17, 2006
His 2 favourite pharmaceuticals are Glaxosmithkline (GSK-N) and Johnson & Johnson (JNJ-N). This company is having so much trouble right now that they are on their 3rd CEO in the last 5/6 years. Have patent problems and sales are declining. Outstanding lawsuits.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$27.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 09, 2006
Big issue is 20% of revenue and a larger % of profits comes from one drug, Lipitor, which will get generic competition. Sold their consumer business and have other products in the pipeline and they are buying back mountains of its own stock. Dividend share is significant.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$26.15

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 03, 2006
A defensive position. Very cheap. Lots of value and seems to have momentum.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$25.51

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 02, 2006
(A Top Pick May 10/06. No change.) A large cap stock that is going into transition. Sold their consumer products area. Wants to see how this affects the balance sheet. 4% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.61

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 25, 2006
All the major drug stocks are starting to act better. In the state of market, money moves from risky stocks to defensive stocks. Has a great yield. A good place to be.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 24, 2006
Under performed Merck (MRK-N) quite dramatically. Between these two would prefer to own Merck. Making a bit of a bottoming pattern which is constructive. Needs to take out some resistance and if they can break through the $26 level there could be some good upside.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.79

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 21, 2006
It has a model price of $33.93 which is a 42% positive differential. Have now sold their consumer division and their balance sheet is going to be a lot smaller. You get the same earnings, but with a smaller balance sheet, which creates, value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.83

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 12, 2006
The drug sector continues to be weak in general and is a group that has under performed during the last 2/3 years. This one has even under performed the group.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$23.18

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 11, 2006
Have cleared their problems with Cellebrex. Selling their consumers product division for $16 billion cash. This will probably go to share repurchase, increased dividends and acquisition of promising drugs from small companies. Cheap.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.49

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2006
Great dividend yield. Probably one of the worst performing sectors in the S&P. Lots of cost cutting opportunities. A number of drugs along the pipeline. Trading at around 8/9 X earnings. Pristine balance sheet.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2006
A real defensive story. Have tremendous internal cash flow. Have a sound dividend and they buy back stocks. A real value play. New drugs coming out are really solid.
Photo of Paul Gardner, CFAPaul Gardner, CFA
Owned
Unlock Rating
$23.11

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 30, 2006
Got rid of a lot of their past problems. The whole drug sector has been a difficult place to be because of pricing pressures, lawsuits, etc. The worst is now over. Large pharmaceuticals are international, so as the US$ drops, their foreign assets increase.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 26, 2006
A cheap company. The sector is cheap. Really great yield. Expects they will be getting rid of their consumer products division this year, which will give the stock a boost.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$23.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 616 to 630 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like